Skip to main content
SpringerLink
Log in

Nivolumab + cabozantinib not cost effective "at current pricing" for advanced RCC in the USA

  • Clinical study
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Reference

  • Liao W, et al. Cost-Effectiveness Analysis of First-Line Nivolumab Plus Cabozantinib for Advanced Renal Cell Carcinoma in the United States. Internet Document : 18 Oct 2021. Available from: URL: https://doi.org/10.1007/s12325-021-01926-0

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Nivolumab + cabozantinib not cost effective "at current pricing" for advanced RCC in the USA. PharmacoEcon Outcomes News 890, 17 (2021). https://doi.org/10.1007/s40274-021-08140-y

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40274-021-08140-y

Search

Navigation